) pipeline looks promising with candidates like BL-5010
(non-surgical removal of skin lesions); BL-1040 (preventing
pathological cardiac remodelling following a myocardial
infarction); BL-8040 (acute myeloid leukemia and other
hematological cancer indications) and BL-7010 (celiac disease).
Earlier in the week BioLineRx announced that results from a phase
I/II study on BL-8040 were published in the journal,
Clinical Cancer Research
. Results showed that BL-8040 allows the efficient mobilization
of stem cells from the bone marrow into the peripheral blood. The
procedure facilitates autologous stem cell transplantation in
patients suffering from multiple myeloma.
Results further revealed that BL-8040 binds with a very high
affinity to CXCR4 and also dissociates from the receptor slowly.
BL-8040 is being evaluated in a multicenter, open-label phase II
study for treating adults suffering from relapsed/refractory
acute myeloid leukemia (AML). The study is also assessing the
pharmacokinetic profile of BL-8040 along with an efficacy
Partial results from the study are expected later this year,
with final results scheduled for the second half of 2014. We are
positive on the company's efforts to develop BL-8040 in oncology.
However, we note that the oncology market is extremely crowded
with the presence of big players like
ACTELION LTD (ALIOF): Get Free Report
BIOLINE RX LTD (BLRX): Get Free Report
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis
ROCHE HLDG LTD (RHHBY): Get Free Report
To read this article on Zacks.com click here.
BioLineRx is also studying BL-8040 for the treatment of
thrombocytopenia (reduced platelet production). In Aug 2013, the
company reported positive results from pre-clinical trials on the
candidate, where it was proved to be effective for the treatment
of thrombocytopenia. Results further revealed that BL-8040
increased the number of megakaryocytes (cells that produce
platelets) within the bone marrow.
We remind investors that in Sep 2012, the rights to BL-8040 were
in-licensed by BioLineRx from Biokine Therapeutics Ltd.
BioLineRx presently carries a Zacks Rank #4 (Sell). Some
better-ranked stocks include
). Both these stocks carry a Zacks Rank #1 (Strong Buy).